Second Phase 3 clinical trial again shows dupilumab lessens disease in COPD patients with type 2 inflammation Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report. This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD.
https://www.sciencedaily.com/r....eleases/2024/05/2405